Galen has enjoyed a long and successful track record of partnering with experienced and driven management teams to build large, sustainable businesses. Galen achieves this by leveraging healthcare experience and a network of industry relationships to help provide management partners with the necessary resources and support to create and implement impressive growth plans.
Since 1990, they have built an investment portfolio with an aggregate market value of over $10 billionâ€“and helped 70 of their portfolio companies navigate through the complicated paths of public offerings, debt financings, and mergers and acquisitions. As such, over the past decade they have gained recognition as one of the largest and most influential names in healthcare private equity investing.
|Quotient Biodiagnostics||2/2013||Private Equity||$5M||2|
|Tactile Systems Technology||10/2012||Series B||$10.4M||2|
|Quotient Biodiagnostics||3/2012||Venture Round||$11.2M||1|
|Nautilus Neurosciences||4/2010||Series A||$10.5M||1|